DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors, 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine), benefit some MDS/AML patients. However, the role of DNA methyltransferase inhibitor-indu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Genome Biology (Online Edition) 2014-08, Vol.15 (8), p.406-406, Article 406
Hauptverfasser:	Lund, Kirstin, Cole, John J, VanderKraats, Nathan D, McBryan, Tony, Pchelintsev, Nikolay A, Clark, William, Copland, Mhairi, Edwards, John R, Adams, Peter D
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Azacitidine - analogs & derivatives Azacitidine - pharmacology Cell Line, Tumor Chemical properties Decitabine DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors DNA Methylation - drug effects Enzyme Inhibitors - pharmacology Gene Expression Regulation, Neoplastic - drug effects Gene Silencing - drug effects Genetic aspects Genetic transcription High-Throughput Nucleotide Sequencing Humans Information management Leukemia, Myeloid, Acute - enzymology Leukemia, Myeloid, Acute - genetics Physiological aspects Promoter Regions, Genetic Sequence Analysis, RNA
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!